Because no public monograph for a fixed-dose Qicao Rukang tablet is available, the following operating windows are derived from standard veterinary oral solid dosage practice for a hygroscopic dried herbal powder and must be justified by the marketing authorization holder. Direct compression is generally not feasible when the particle size distribution exceeds a D90 of 250 μm, as the dried herbal matrix exhibits low compaction propensity under a compression force of 5-12 kN. A wet granulation route is therefore selected. The powder is passed through a vibratory sieve fitted with a 0.710 mm mesh and pre-blended with microcrystalline cellulose and lactose monohydrate at a typical ratio of 20.0-35.0% w/w API, 30.0-50.0% w/w filler, 3.0-5.0% w/w croscarmellose sodium, and 2.0-5.0% w/w povidone K30 as a binder. Purified water is added at 8.0-12.0% w/w of dry blend mass in a high-shear granulator with an impeller tip speed of 3-6 m/s until the wet mass reaches an end-point sieved through a 1.0 mm screen. Granules are dried in a fluid-bed dryer at inlet air 55 ± 5 °C to a final loss-on-drying range of 2.0-5.0% w/w, monitored according to Ph. Eur. 2.2.32. After cooling, the granules are lubricated with 0.5-1.0% w/w magnesium stearate screened through a 500 μm sieve and compressed on a rotary tablet press with a pre-compression force of 3-5 kN and a main compression force of 8-15 kN to produce scored tablets of 0.50-1.00 g mean weight. Finished tablets are tested for uniformity of dosage units according to USP <905>, disintegration according to USP <701>, and dissolution according to USP <711>, as well as the general tablet monograph in the Chinese Veterinary Pharmacopoeia 2020 edition, General Chapter 0101. The process must be operated in a cleanroom meeting ISO 14644-1:2015 class 8 for non-sterile oral solid dosage handling. Batch-to-batch variance in herbal extract moisture content above 6.0% w/w can cause picking and sticking on punch faces; pre-drying at 50 °C for 6 h is required when relative humidity exceeds 60%. Blister packaging with aluminium foil and PVC/PVDC laminate is used as the terminal packaged configuration, and stability evaluation follows VICH GL18(R) zone II conditions of 25 °C/60% RH for a proposed shelf life of 24 months.

What limits the sterility assurance level when Qicao Rukang Powder is converted into an injectable solution?

The conversion of a crude herbal powder API into an injectable dosage form is constrained by insoluble plant cell fragments, high endotoxin load, and thermolabile secondary metabolites, none of which can be assumed to survive terminal sterilization without assay validation. Published data for this specific injectable configuration is limited; therefore, the extraction and filtration window is derived from standard botanical parenteral manufacturing. The powder is first extracted with water for injection at 60 ± 2 °C for 2 h under continuous stirred-tank extraction at a powder-to-solvent ratio of 1:10 w/v, followed by cold precipitation at 2-8 °C for 12-24 h and centrifugation at 10,000 × g to remove high-molecular-weight polysaccharides and polyphenols that would otherwise foul the sterilizing filter. The clarified bulk solution is adjusted to a target native-powder equivalent concentration of 5.0-10.0% w/v, with osmolality adjusted using sodium chloride to a target of 285-310 mOsm/kg and pH adjusted to 5.5-6.5 with phosphate buffer. Prefiltration through a 0.45 μm polypropylene filter is followed by sterile filtration through a 0.22 μm PVDF or PES membrane under differential pressure less than 0.5 bar; filter integrity testing by bubble point must be performed before and after filtration according to the filter manufacturer’s specified minimum bubble point. The filtrate is filled into 10 mL type I borosilicate glass vials under ISO 14644-1:2015 class 5 unidirectional airflow, with fill volume controlled to 10.5 ± 0.2 mL. If thermal stability of marker compounds is demonstrated, terminal sterilization may be carried out at 121 °C for 15 min; otherwise aseptic filtration remains the default when a sterility assurance level of 10⁻⁶ cannot be thermally validated. Compliance is anchored to 21 CFR 210.3 and 211.94, USP <1>, USP <85>, USP <788>, VICH GL18(R), and the Chinese Veterinary Pharmacopoeia 2020 injection monograph. Endotoxin limits must be set at ≤ 0.5 EU/mg of dry API unless justified by the approved veterinary drug application. The terminal finished product is a clear to slightly opalescent injectable solution intended for intramuscular or subcutaneous administration only after batch release data for potency, pH, sterility, and endotoxin have been obtained.

Capsule fill weight variability is governed by powder flow function coefficients

For hard gelatin capsule filling, Qicao Rukang Powder must be converted into a free-flowing granulate because the raw powder often exhibits a Jenike flow function coefficient below 2.0, indicating a cohesive or strongly cohesive bulk solid according to ASTM D6128-16. The dry granulation route is preferred when moisture exposure must be minimized. The powder is compacted on a roller compactor at roll pressure 2.0-3.5 MPa, roll speed 3-5 rpm, and granulator sieve size 0.8 mm. The resulting granules are blended at an API load of 20.0-40.0% w/w, with microcrystalline cellulose as the primary filler at 45.0-60.0% w/w, croscarmellose sodium at 3.0-5.0% w/w, colloidal silicon dioxide at 0.5-1.0% w/w, and magnesium stearate at 0.5-1.0% w/w. The blend is filled into size 0 or 1 hard gelatin capsules on an automatic capsule-filling machine with dose weight variation controlled to ± 5% relative to target. Finished capsules are tested according to USP <905>, USP <701>, and USP <711>, with dissolution testing conducted in 900 mL purified water at 37 ± 0.5 °C using Apparatus II at 50 rpm. Capsule shell moisture must be maintained between 13.0-16.0% w/w to prevent brittle fracture; storage below 40% RH at 25 °C can induce shell cracking. Packaging in PVC/PVDC blisters is required in high-moisture zones, and stability follows VICH GL18(R) at 25 °C/60% RH with a proposed shelf life of 24 months. Batch processing must comply with 21 CFR 211.80 and 211.113 for component handling and microbial limits, as well as the Chinese Veterinary Pharmacopoeia 2020 capsule general chapter.

Oral powder dosage is selected when dose flexibility and rapid reconstitution in drinking water or milk replacer outweigh the requirements of taste masking and controlled delivery. Qicao Rukang Powder is first milled through a 0.250 mm sieve to achieve a D90 below 180 μm and then diluted with lactose monohydrate carrier in a ribbon blender at a geometric dilution sequence of 1:5, 1:10, 1:20 until a final API concentration of 5.0-25.0% w/w is achieved. The blend is mixed for 20 min at 15-20 rpm, and homogeneity is confirmed by collecting 10 stratified samples with a sampling thief and assaying the marker compound by HPLC; the coefficient of variation must not exceed 5.0%. After blending, the powder is filled into 100 g or 500 g LDPE sachets using an auger filler with average fill weight control at ± 2.0%. Microbial quality is controlled according to 21 CFR 211.113 and the Chinese Veterinary Pharmacopoeia 2020 microbial limits for oral veterinary preparations; total aerobic microbial count must be below 10³ CFU/g, and Escherichia coli must be absent in 1 g. The finished sachet configuration exposes the hygroscopic powder to ambient moisture through the LDPE seal; therefore, seal strength must exceed 3 N/15 mm when tested according to ASTM F88/F88M-21. Segregation of fine API particles from the carrier during transport can occur if the bulk density difference exceeds 0.2 g/cm³; carriers with a tapped density within 10% of the active powder are selected to prevent this failure mode. Stability evaluation follows VICH GL18(R) at 30 °C/65% RH and 25 °C/60% RH as a bracketing study, with moisture uptake measured at 0, 3, 6, 12, 18, and 24 months.

When the powder is incorporated into a granule dosage form, the wet mass torque curve end-point must be validated against sieve retention

The granule route is adopted when the final product must be mixed into feed or administered as a drench feed additive with improved palatability and reduced dusting. Qicao Rukang Powder is pre-blended with sucrose or mannitol at an API load of 10.0-30.0% w/w, starch at 5.0-15.0% w/w, and a binder solution of povidone K30 at 3.0-5.0% w/w solids. The dry blend is loaded into a high-shear granulator with a bowl capacity of 100 L; impeller speed is set at 200 rpm, chopper speed at 1500 rpm, and binder solution is sprayed at 20-30 L/h until measured torque reaches a plateau of 5-8 Nm, corresponding to a crumb-like wet mass. The wet granules are discharged and wet-milled through a 1.25 mm sieve, then dried in a fluid-bed dryer with inlet air temperature 60 ± 5 °C until loss on drying is 1.5-3.0% w/w as determined by Ph. Eur. 2.2.32. Dried granules are dry-sieved through a 0.500-1.000 mm fraction; fines below 0.250 mm are recycled at 10-20% w/w into the next granulation batch to maintain granule size distribution. The final granulate is filled into stick packs of 5 g or 20 g at a fill weight variation below ± 5%. Process validation must include torque end-point correlation with sieved granule retention on 0.500 mm sieve, targeting 50-70%, and bulk density of 0.45-0.65 g/cm³ to prevent segregation during filling and transport. Compliance is maintained with 21 CFR 211.110, VICH GL18(R), and the general granule chapter of the Chinese Veterinary Pharmacopoeia 2020. The finished granules are packaged in multi-layer sachets with a water vapor transmission rate below 0.1 g/m²/day at 38 °C/90% RH; moisture uptake above 3.0% w/w after opening is considered a critical quality defect because it triggers caking and loss of dispensability.

Medicated premix manufacturing with Qicao Rukang Powder is governed by carrier density matching rather than by binder addition, because the final premix is intended for subsequent dilution at the feed mill or on-farm mixer. The API is first milled to a mean particle size of 100-200 μm and then mixed with a rice hull or calcium carbonate carrier that has been sieved to 250-500 μm; the carrier tapped density must be within 10% of the API tapped density to hold segregation index below 5% after 10 pneumatic transfer cycles. A stepped geometric dilution sequence of 1:10, 1:100, 1:1000 is executed in a ribbon mixer with an effective volume of 500 L, fill level controlled to 60-70% of rated capacity, and mixing time of 15 min at 20 rpm. Typical API concentration in the final premix is 1.0-10.0% w/w, with the remainder comprising carrier and 0.5-1.0% w/w of a food-grade anticaking agent such as colloidal silicon dioxide. The finished premix is filled into 25 kg multi-wall paper bags with an inner polyethylene liner, and the heat seal is tested for integrity according to ASTM F88/F88M-21. Homogeneity testing is conducted by collecting 20 samples across the batch and analyzing the active marker content; the coefficient of variation must not exceed 5.0% for a production-scale batch. Compliance is anchored to Regulation (EU) 2019/4 for medicated feed, 21 CFR Part 225 for current good manufacturing practice for medicated feeds, and the Chinese Veterinary Pharmacopoeia 2020 premix monograph. Because the premix is diluted into complete feed at the farm, carry-over and equipment flush testing must demonstrate that the subsequent non-medicated batch contains below the limit of detection of the marker compound; published data for this specific API in feed matrices is limited, so the limit of detection must be established by the marketing authorization holder using a validated HPLC or LC-MS/MS method. Storage is maintained at 25 °C and 60% RH for 12 months if the inner liner remains intact; breach of the liner raises the moisture sorption rate above 2.0% w/w per month under tropical conditions.

Oral solution viscosity, preservative threshold limits, and settling index

For oral solution or liquid drench application, the water-soluble fraction of Qicao Rukang Powder is extracted rather than suspending the full crude powder, because suspended particles above 50 μm create nozzle clogging in automatic drenching equipment and caking at the bottle neck. The extraction is carried out with purified water at a powder-to-solvent ratio of 1:10 w/v at 60 °C for 2 h, followed by filtration through 10 μm and 1.0 μm bag filters and a final 0.45 μm cartridge filter. The bulk liquid is adjusted to a native-powder equivalent concentration of 2.0-10.0% w/v, with glycerin at 10.0-20.0% v/v to increase viscosity to 10-50 mPa·s and reduce settling of any residual submicron particles, sodium benzoate at 0.1-0.3% w/v as a preservative, and citric acid/sodium citrate buffer to maintain pH at 4.0-5.5. The solution is mixed under high shear at 3000 rpm for 30 min and then deaerated under vacuum at 0.5 bar to remove entrapped air that would otherwise alter fill volume and cause oxidative degradation. The liquid is filled into 500 mL or 1 L HDPE bottles with tamper-evident caps, with fill volume tolerance of ± 1.5%. Final product testing includes pH, relative density, viscosity, microbial limits according to USP <1111> and the Chinese Veterinary Pharmacopoeia 2020 oral liquid monograph, and preservative antimicrobial effectiveness testing according to USP <51>. Because the solution is intended for oral administration in drinking water lines, dilution stability at 1:100 v/v in hard water with 300 mg/L CaCO₃ equivalent must be evaluated for 24 h at 25 °C; published data for this specific formulation is limited, so the marketing authorization holder must generate in-use dilution stability data before field use. Packaging must comply with 21 CFR 211.94 and Regulation (EU) 2019/6, and stability is evaluated under VICH GL18(R) conditions of 25 °C/60% RH and 30 °C/65% RH with a proposed shelf life of 18 months.